4.7 Article

Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes

Journal

DIABETES OBESITY & METABOLISM
Volume 23, Issue -, Pages 50-62

Publisher

WILEY
DOI: 10.1111/dom.14200

Keywords

bariatric; metabolic surgery; comprehensive lifestyle programme; diet; medications for obesity; personalized obesity management

Ask authors/readers for more resources

In the context of obesity as a major public health problem, this paper examined the effectiveness of weight loss for obese patients, the current therapies available, and strategies to improve patient outcomes based on evidence-based studies. Current treatments, including lifestyle, diet, and medications, typically result in a 5% to 7% reduction in weight. While low carbohydrate diets do not show significant advantages over low fat diets, medications approved for long-term management of obesity are not as effective as surgery. Personalized approaches based on genotype or phenotype have not shown consistent success in weight loss treatments.
Against the backdrop of obesity as a major public health problem, we examined three questions: How much weight loss is needed to benefit patients with obesity? How well do current therapies do in producing weight loss? What strategies can be used to improve patient outcomes using evidence-based studies. This paper reviews literature on the outcomes of lifestyle, diet, medications and surgical treatments for obesity using literature searches for obesity treatments. Current treatments, including lifestyle, diet and exercise, produce a weight loss of 5% to 7% on average. Despite continued attempts to identify superior dietary approaches, most careful comparisons find that low carbohydrate diets are not significantly better than low fat diets for weight loss. The four medications currently approved by the US Food and Drug Administration for long-term management of obesity are not as effective as surgery, adding about 5% on average to lifestyle approaches to weight loss. Two new medications that are under investigation, semaglutide and tirzepatide, significantly improve on this. For all treatments for weight loss, including lifestyle, medications and surgery, there is enormous variability in the amount of weight lost. Examination of this literature has yielded evidence supporting baseline and process predictors, but the effect sizes associated with these predictors are small and there are no prospective studies showing that a personalized approach based on genotype or phenotype will yield uniform success. Because obesity is a chronic disease it requires a 'continuous treatment model' across the lifespan.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available